FDA Clearance Tracker · P980033-S050
VENOUS WALLSTENT
Last checked: Nov 20, 2026Latest source record: Mar 17, 2020 (this decision)Source: openFDAMethods & limitations
Decided
Mar 17, 2020
Approved
Time to decision
557 days
Received Sep 7, 2018. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P980033-S050
- Device name
- VENOUS WALLSTENT
- Applicant
- Boston Scientific Corporation
- Applicant location
- Maple Grove, MN
- Received
- Sep 7, 2018
- Decided
- Mar 17, 2020
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P980033
Device type
- Device type
- Stent, iliac vein (QAN)
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
Approval for the VENOUS WALLSTENT for expanding the indications to include improving luminal diameter in the iliofemoral veins for the treatment of symptomatic venous outflow obstruction. This device is indicated for the following: The VENOUS WALLSTENT is indicated for improving central venous luminal diameter following unsuccessful angioplasty in patients on chronic hemodialysis with stenosis of the venous outflow tract. Unsuccessful angioplasty is defined as residual stenosis >= 30% for a vein <= 10mm in diameter or >= 50% for a vein > 10 mm in diameter; a tear which interrupts the integrity of the intima or lumen; abrupt lesion site occlusion, or refractory spasm. The vessels that can be treated with the VENOUS WALLSTENT are the innominate and subclavian veins, ranging from 8 mm to 15 mm in diameter. The VENOUS WALLSTENT is also indicated for improving luminal diameter in the iliofemoral veins for the treatmet of symptomatic venous outflow obstruction.
Source documents
Other decisions for Boston Scientific Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- SpaceOAR Flex System510(k)
K262151 · Decided Sep 11, 2026 · 78 days after receipt
Device type: Hydrogel Spacer (OVB) · Radiology & Imaging
K261153 · Decided Aug 26, 2026 · 140 days after receipt
Device type: Ureteroscope And Accessories, Flexible/Rigid (FGB) · GI, Urology & Nephrology
K261915 · Decided Aug 4, 2026 · 56 days after receipt
Device type: Endoscopic Access Overtube, Gastroenterology-Urology (FED) · GI, Urology & Nephrology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.